Fig. 1: Equivalent WT and beta (B.1.351) IgG1 S-specific antibody levels and neutralization titers across vaccinees who either developed COVID-19 or were uninfected. | Nature Immunology

Fig. 1: Equivalent WT and beta (B.1.351) IgG1 S-specific antibody levels and neutralization titers across vaccinees who either developed COVID-19 or were uninfected.

From: ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19

Fig. 1

a,b, Violin plots showing the univariate comparison of WT (a) and beta B.1.351 (b) SARS-CoV-2 S-specific IgG levels between vaccinees who resisted COVID-19 (n = 140) and individuals who developed COVID-19 (n = 30) over the study period. MFI, mean fluorescence intensity. c,d, SARS-CoV-2 WT (c) and beta B.1.351 (d) neutralization titers measured for vaccinees who resisted COVID-19 (n = 28) or developed beta VOC COVID-19 (n = 12). A Mann–Whitney U-test was used to define differences and the Benjamini–Hochberg method was used to adjust for multiple comparisons, with an adjusted P (Padj): ***P < 0.001; **P< 0.01; *P < 0.05.

Source data

Back to article page